NLS Pharmaceutics Ltd.
NCEL
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for rare and complex central nervous system (CNS) disorders. Headquartered in Zurich, Switzerland, the company leverages advanced scientific platforms, including its proprietary dual orexin receptor agonist (DOXA) technology, to target neurobehavioral and neurocognitive challenges such as narcolepsy, ADHD, and other sleep-related conditions. NLS Pharmaceutics is committed to delivering safer, more effective treatments that address significant unmet medical needs in the global CNS therapeutics market. Its pipeline includes lead candidates like Mazindol ER, designed to improve symptoms in patients with narcolepsy and ADHD, as well as other investigational assets targeting neurodegenerative diseases. The company’s research is supported by a network of world-class partners and scientists, emphasizing rigorous clinical development and robust intellectual property. In October 2025, NLS Pharmaceutics completed a strategic merger with Kadimastem Ltd., forming NewcelX Ltd., which consolidates expertise in both drug development and cell therapy to broaden its impact across neurodegenerative diseases and diabetes. This evolution positions the company at the forefront of next-generation CNS therapies, combining cutting-edge science with a patient-centric approach to drive meaningful advances in brain health.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$8M
▼ -15.3% YoY
Op. Margin
–
ROIC
-38.06%
▲ +12.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▼ -158.8% YoY
Op. Cash Flow (TTM)
-$3M
▼ -146.6% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$2M
Continue Research
Peers
Biotechnology · Pick stocks to compare with NCEL
NLS Pharmaceutics (NCEL) in three numbers
Questions about NLS Pharmaceutics
Is NLS Pharmaceutics a high-quality business?
NLS Pharmaceutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$2M, and its weakest is return on capital at -38.1%. The Quality tab shows every check against its target.
Does NLS Pharmaceutics (NCEL) pay a dividend?
No. NLS Pharmaceutics (NCEL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NCEL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.